Topic: venture capital (VC)
In response to declining venture investment in some disease areas, BIO is releasing reports to identify barriers to innovation.
Chinese biotech Innovent Biologics is reportedly considering a $200 million IPO later this year that could take place in the U.S.
The €8.7 million series B will support studies targeting two bacterial infections and the creation of a drug manufacturing unit.
The financing equips Stimwave to push ahead with its previously disclosed plans to make its devices available across the U.S.
The French VC shop moved quickly to put the initial $102 million to use by setting up and financing three startups in its home country.
The Minneapolis-based medtech firm is aiming to improve glucose control in diabetics by ablating nerves linked to metabolic organs.
The partners will create a joint fund that invests in technologies globally and then seeks to accelerate their progress in China.
KBP Biosciences has raised $76 million as it eyes a new headquarters in the U.S. and a new chief executive in the form of ex-GSK vet Brian McVeigh.
The series B gives PGDx the means to pursue approvals of its tissue and liquid biopsy IVD cancer tests in markets around the world.
The round positions BioNTech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by modalities including CAR-T cells.